Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Refers Wellbutrin SR, Zyban To NIH For Pediatric Studies

Executive Summary

FDA is requesting that the National Institutes of Health conduct pediatric studies on GlaxoSmithKline's bupropion agents Wellbutrin SR and Zyban

You may also be interested in...



FDA Requests Antidepressant Labeling Add Suicidality Warning

FDA is requesting that labeling for 10 antidepressants include a warning recommending close monitoring of adult and pediatric patients for suicidal behavior

Wellbutrin SR Generics Multiply As Andrx Relinquishes Exclusivity

Andrx' agreement to give up its first-to-file ANDA exclusivity on a generic of GlaxoSmithKline's Wellbutrin SR 150 mg tablet means six companies will immediately share in the profits on sales of the generic antidepressant

Pediatric Off-Patent Study Requests Will Not Mirror Rate For Exclusivity

FDA does not expect to issue written requests for studies of off-patent drugs at the same rate it has for patented drugs seeking pediatric exclusivity, Office of Counterterrorism & Pediatric Drug Development Director Dianne Murphy, MD, said

Related Content

UsernamePublicRestriction

Register

PS043762

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel